|
Therapeutic Areas
|
Innovative Drug Candidates
|
Key Indications
|
IND Enabling
|
IND
|
Phase Ⅰ
|
Phase Ⅱ
|
Phase Ⅲ
|
NDA
|
|
Oncology
|
BH009
|
Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Cancer
|
|
|
|
|
|
|
|
Head and Neck Tumors, Ovarian Cancer
|
|
|
|
|
|
|
|
Triple-Negative Breast Cancer
|
|
|
|
|
|
|
|
BH002
|
Advanced Prostate Cancer
|
|
|
|
|
|
|
|
BH011
|
Non-Muscle-Invasive Bladder Cancer
|
|
|
|
|
|
|
|
Non-Muscle-Invasive Bladder Cancer
|
|
|
|
|
|
|
|
BH015
|
Non-Muscle-Invasive Bladder Cancer
|
|
|
|
|
|
|
|
Oncology(PDC)
|
BH-259
|
Solid Tumors
|
|
|
|
|
|
|
|
BH-1621
|
Solid Tumors
|
|
|
|
|
|
|
|
PDC-3
|
Solid Tumors
|
|
|
|
|
|
|
|
Non-Oncology
|
BH006
|
Chemotherapy-Induced Nausea and Vomiting
|
|
|
|
|
|
|
|
BH007
|
Postoperative Pain Management
|
|
|
|
|
|
|
